Mittendorf, Elizabeth A.
Kantor, Olga
Weiss, Anna
Richardson, Edward
Garrido-Castro, Ana
Portnow, Leah H.
Krop, Ian E.
Lin, Nancy U.
Winer, Eric P.
Tolaney, Sara M.
King, Tari A.
Article History
Received: 14 March 2022
Accepted: 8 July 2022
First Online: 8 August 2022
Disclosure
: E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences (formerly Genomic Health), Merck, Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. A.W. reports institutional research support from Myriad. E.R. reports institutional research support from AstraZeneca. A.G.C. reports institutional research support from AstraZeneca, Gilead, and Merck. I.E.K. reports employment from AMAG Pharmaceuticals and Freeline Therapeutics; stock and other ownership interests from AMAG Pharmaceuticals, Freeline Therapeutics, and Vertex; honoraria from AstraZeneca, Roche/Genentech, and Celltrion; consulting or advisory role for AstraZeneca, Bristol Myers Squibb, Context Therapeutics, Daiichi Sankyo, Macrogenics, Merck, Novartis, Roche/Genentech, Seattle Genetics, and Taiho Pharmaceutical; and institutional research support from Roche/Genentech and Pfizer. N.U.L. reports stock and other ownership interests from Artera Inc.; consulting or advisory role for Affinia Therapeutics, Aleta Biopharma, AstraZeneca, Daichii-Sankyo, Denali Therapeutics, Olema Pharmaceuticals, Prelude Therapeutics, Puma, and Voyager Therapeutics; and institutional research support from AstraZeneca, Merck, Olema Pharmaceuticals, Roche/Genentech, Seattle Genetics, and Pfizer. E.P.W. reports honoraria from Exact Sciences (formerly Genomic Health) and Roche/Genentech; consulting or advisory role for Athenex, Carrick Therapeutics, G1 Therapeutics, GlaxoSmithKline, Gilead, Jounce Therapeutics, Leap Therapeutics, Lilly, Roche/Genentech, Syros Pharmaceuticals, and Zymeworks; and institutional research support from Roche/Genentech. S.M.T. reports consulting or advisory role for 4D Pharma, ARC Therapeutics, AstraZeneca, Athenex, BeyondSpring Pharmaceuticals, Blueprint Medicine, Bristol Myers Squibb, Certara, CytomX Therapeutics, Daiichi Sankyo, Eisai, Ellipses Pharma, G1 Therapeutics, Gillead, Kyowa Hakko Kirin, Lilly, Merck, Mersana, Nanostring Technologies, Nektar, Novartis, Odonate, OncoPep, OncoSec Medical, OncXerna, Paxman, Pfizer, Puma Biotechnology, Reveal Genomics, Roche/Genentech, Samsung Bioepis, Sanofi, Seattle Genetics, Silverback Therapeutics, Zentalis, and Zymeworks; and institutional research support from AstraZeneca, Bristol Myers Squibb, Cyclacel, Eisai, Exelixis, Gilead, Lily, Merck, Nanostring, Nektar, Novartis, Odonate Therapeutics, Roche/Genentech, Sanofi, Seattle Genetics, and Pfizer. T.A.K. reports speakers honoraria and compensated service on scientific Advisory Board of Exact Sciences (formerly Genomic Health); compensated service as faculty, PrecisCa cancer information service; and compensated service for a Global Advisory Board of Berins Healthcare.